Primary clear cell microcystic adenoma of the sinonasal cavity: pathological or fortuitous association? by Cooper, Rosalin et al.
   
  Primary Clear Cell Microcystic Adenoma of the Sinonasal Cavity: 
Pathological or Fortuitous Association? 
Rosalin Cooper1, Hannah Markham1, Jeffery Theaker1, Adrian Bateman1, David Bunyan2, 
Matthew Sommerlad1, Gillian Crawford3, Diana Eccles3 
1Department of Cellular Pathology, University Hospital Southampton NHS Foundation Trust, Southampton, UK 
2Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury, UK 
3(1)University of Southampton, Southampton, UK and (2) Wessex Clinical Genetics Service, University Hospitals 
Southampton NHS Foundation Trust, Southampton, UK 
 
Primary clear cell microcystic adenoma of the sinonasal cavity is rare. It has previously been 
described only as a VHL-associated tumour. Von-Hippel Lindau (VHL) syndrome is an inherited 
cancer syndrome characterised by an elevated risk of neoplasia including clear cell renal cell 
carcinoma (ccRCC), haemangioblastoma and phaeochromocytcoma. We describe the second reported 
case of a primary clear cell microcystic adenoma of the sinonasal cavity. The 39 year old patient with 
VHL syndrome had previously undergone resection and ablation of ccRCC. He presented with 
epistaxis. Imaging demonstrated a mass in the ethmoid sinus. Initial clinical suspicion was of 
metastatic ccRCC. However, tumour morphology and immunoprofile were distinct from the previous 
ccRCC and supported a diagnosis of primary microcystic adenoma. Analysis of DNA extracted from 
sinonasal tumour tissue did not show loss of the wild type allele at the VHL locus. Although this did 
not support tumour association with VHL disease, it was not possible to look for a loss-of-function 
mutation. The association of primary microcystic adenoma of the sinonasal cavity with VHL disease 
remains speculative. These lesions are benign but are likely to require regular surveillance. Such 
tumours may require repeated surgical excision.  
1. INTRODUCTION 
Von Hippel-Lindau (VHL) disease is a cancer syndrome characterised by an increased risk of 
multiple tumour types occurring across different organ systems. These include haemangioblastomas 
within the central nervous system, and characteristic visceral lesions including clear cell renal cell 
carcinoma (ccRCC) and phaeochromocytoma [1]. Microcystic pancreatic lesions can also occur in the 
context of VHL disease [2]. Affected individuals carry germline mutations in the VHL tumour-
suppressor gene with loss of the wild-type allele (normal gene copy) in a VHL disease-associated 
organ system leading to tumour formation [1,3].  
Sinonasal tumours are rare [4,5]. Common benign lesions include inverted papillomas and osteomas 
[4], whilst common malignant lesions include squamous cell carcinoma and adenocarcinoma [5]. 
There has been only one reported case of a primary clear cell microcystic adenoma of the sinonasal 
cavity in the literature [6]. In this previously reported case, molecular analysis of tumour DNA 
confirmed tumour VHL disease association. Here we describe the second reported case of primary 
clear cell microcystic adenoma of the sinonasal cavity. 
2. CASE REPORT 
2.1 Clinical History 
A 39 year old man with molecularly confirmed VHL disease presented with epistaxis in 2012. 
Molecular analysis had confirmed a germline VHL mutation in 2004. He had previously undergone 
excision of cerebellar haemangioblastoma in 2003. He had also undergone bilateral nephron sparing 
surgery for ccRCC (stage pT1a, Fuhrman grade up to 3) in 2005 and renal radiofrequency ablation in 
both 2008 and 2012. CT imaging demonstrated an ethmoid mass measuring 35×34×44mm. The 
patient underwent endoscopic transphenoidal resection of the lesion. Staging investigations were 
negative for metastatic disease. 
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Two years later, in 2014, the patient developed symptoms of nasal obstruction. Sinonasal tumour 
recurrence was suspected. Imaging demonstrated limited progression in the nasal cavity. Excision 
biopsy was performed. Histology appeared consistent with the initial presenting sinonasal tumour. 
Excision appeared complete, with no evidence of residual tumour. Subsequently, symptoms recurred. 
Therapeutic excision was performed in 2015 and again in 2016. To date, the patient’s VHL disease 
remains stable with no evidence of new lesions or metastatic disease. 
The patient remained under the management of specialist multi-disciplinary (MDT) team which co-
ordinated regular imaging surveillance and clinical review. The MDT recommended regular magnetic 
resonance imaging (MRI) surveillance with localised resection as applicable. More extensive surgery 
or adjuvant therapy was not felt to be indicated. 
2.2 Histology 
Slides of the sinonasal tumour resected in 2012 and the patient’s ccRCC resected in 2005 were 
collated to allow comparison. Immunohistochemical and special stains for CD10, RCC, CK7, CK20, 
epithelial marker AE1/3, vimentin, EMA, Ki67, ssms1, sma, alpha-inhibin, p63, thyroglobulin, NSE, 
s100, GFAP and PAS were performed according to standard automated protocols (Dako, UK).  
 
                   
 
 
The sinonasal tumour demonstrated tubulocystic morphology with a brush border, glycogen-rich cells 
and low grade nuclei without conspicuous mitoses (Figure 1A, 1B). The renal tumour consisted of 
clear tumour cells with tubulopapillary morphology with hobnailing at the luminal surface with 
Fuhrman grade up to 3 (Figure 1C, 1D).  
The sinonasal tumour was positive for CK7, epithelial marker AE1/3, vimentin, NSE and EMA, with 
patchy CK20 staining, but negative for RCC and CD10. Secretions were PAS-positive and Ki67 
demonstrated a low proliferation index. Immunohistochemistry revealed renal tumour positivity for 





FIGURE 1: Haematoxylin and eosin (HE) stains of the sinonasal 





































































Luminal secretions positive 
FIGURE 4: Immunohistochemical profile of the renal and sinonasal tumours 
FIGURE 2: Immunohistochemistry (IHC) of renal and sinonasal tumours, x2. (A) Sinonasal tumour cells 
were negative for CD10. (B) Renal tumour cells were strongly positive for CD10. (C) Sinonasal tumour cells 
were negative for RCC, however weak staining of luminal secretions was seen. (D) Renal tumour cells 
demonstrated strong positivity for RCC marker. (E) Sinonasal tumour cells demonstrated positive for CK7. 
(E) The renal tumour was negative for CK7, however in this image a proximal renal tubule was seen to exhibit 
CK7 positivity. (F) The sinonasal tumour exhibited patchy CK20 positivity. (G) The renal tumour was 
negative for CK20.  
 
 
FIGURE 3: (A) Sinonasal tumour with luminal PAS-positive secretions, 











   
2.3 VHL sequencing analysis 
The patient was known to have a constitutional deletion of exon 1 of VHL confirmed by germline 
DNA analysis in 2004. DNA extracted from the sinonasal tumour resected in 2012 underwent 
molecular analysis in 2015 for loss of heterozygosity (LOH) at the VHL locus.  
Point mutation analysis of the three coding exons of VHL (Genbank accession number NM_000551.3) 
was carried out by direct sequencing analysis of sinonasal FFPE-extracted tumour DNA. PCR 
products were generated using a PCR reaction with a 25µl volume and a 60oC annealing temperature 
using exon primers; 1F-tccgacccgcggatccc, 1R-tcagaccgtgctatcgtcc, 2F-gacgaggtttcaccacgtta, 2R-
tcaagtggtctatcctgtact, 3F-tcgttccttgtactgagacc and 3R-gtaccatcaaaagctgagatg. For the exon 1 fragment 
5µl of Q solution was added to the PCR reaction (Qiagen, Manchester, UK). Products were sequenced 
using the Big-Dye® Terminator v1.1 Cycle Sequencing Kit standard protocol (Applied Biosystems, 
USA) and separated on an ABI 3130xl Genetic Analyzer (Applied Biosystems, USA). Data was 
analysed using Mutation Surveyor (version 3.1) software (SoftGenetics, USA). Dosage analysis was 
attempted using the Multiplex Ligation-dependent Probe Amplification (MLPA) method [7], but this 
failed due to sample quality. 
Analysis of tumour DNA demonstrated no causative mutations; however, the tumour was 
heterozygous for an intron 1 polymorphism (c.341-50G>A), reducing the likelihood of LOH.  
3. DISCUSSION 
Primary tumours of the nasal cavity are rare [4,5]. Metastases from other primary tumour sites, whilst 
unusual, may also occur in this region, including those from a primary ccRCC [8-10]. To date, there 
has been one reported case of a primary clear cell microcystic adenoma occurring within the sinonasal 
cavity. This occurred in the context of VHL disease [6].   
In the case we present here the initial clinical suspicion was of metastatic ccRCC. Histologically, the 
clear tumour cells, cystic morphology and positive staining for AE1/3 [11] and vimentin [12] were 
supportive of this diagnosis. However, CD10 and RCC negativity, both of which were expressed by 
the previously resected renal tumour, was not consistent with this interpretation [13]. The tubulocystic 
morphology, brush border and presence of PAS positive secretions were also distinct from ccRCC. 
Furthermore, the tubulocystic morphology, low Ki67 index and absence of conspicuous mitoses were 
dissimilar from a primary sinonasal clear cell carcinoma. Sinonasal clear cell carcinomas are rare. 
These tumours tend to form sheets without glandular structures [14]. They can be locally invasive 
[15]. Such tumours may also metastasize [15].  
In the previously reported case of a primary clear cell microcystic adenoma of the nasal sinus, Xu et 
al. describe microcystic tumour morphology, clear glycogen-rich cells without nuclear atypia, EMA 
and cytokeratin positivity, and negativity for CD10 [6]. These features are consistent with those of the 
case presented here. Similarity was also noted between features of the sinonasal tumour and those of 
pancreatic microcystic adenoma. Typically these pancreatic tumours, which can be both VHL-
associated and sporadic, are characterised by cystic morphology, glycogen rich-cytoplasm, a low 
mitotic index and AE1/3 positivity [2]. These are benign lesions [2]. Conventionally, small lesions in 
asymptomatic patients managed conservatively with regular imaging surveillance. Surgical resection 
is considered for larger, or symptomatic tumours [16]. It is possible that the primary microcystic 
adenoma of the sinonasal tract is a similar tumour entity.  
Xu et al. demonstrated sinonasal microcystic adenoma VHL LOH [6]. This confirmed tumour 
association with VHL disease [6]. In the case we describe here the sinonasal tumour was 
heterozygous at the VHL locus. The presence of an intron 1 polymorphism makes LOH unlikely. 
Therefore, molecular analysis did not support tumour association with VHL disease. However, it was 
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not possible to test for a loss-of-function tumour mutation. It is also feasible that heterogeneity of the 
tumour means that this result is not truly representative of LOH status.  
In the World Health Organisation (WHO) classification of head and neck tumours, adenomatous 
lesions of the sinonasal cavity are of salivary gland origin [17]. However, benign microcystic lesions 
similar to the case reported here are not described within the current classification. Due to the rarity of 
this tumour entity and uncertainty regarding its biological history, categorisation under the current 
WHO classification is not meaningful. In view of the morphological features, immunoprofile, and 
similarities to microcystic lesions in the pancreas and previously reported case we feel that the lesion 
is best described as a microcystic adenoma.  
The sinonasal microcystic adenoma described by Xu et al. was surgically resected due to local 
progression. However, the clinical course of such tumours is unknown [6]. In the case described here, 
following initial surgical excision, to date three further therapeutic excisions have been required due 
to local recurrence. The rapid local recurrence is suggestive of a fast-growing lesion, despite the low 
mitotic index. Therefore, regular imaging surveillance may be indicated, and surgical resection may 
be appropriate.  
4. CONCLUSIONS 
In conclusion, the association of primary microcystic adenoma of the sinonasal cavity with VHL 
disease is possible but not proven. Such lesions are rare and may provide a considerable diagnostic 
challenge. Importantly, these lesions are considered essentially benign. However, they may have 
potential for rapid growth and local recurrence. This suggests that in such cases regular surveillance is 
merited and that repeated surgical resection may be required. 
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